ABSOLUTE BENEFIT OF LENVATINIB PLUS ANTI-PD-1 FOR UNRESECTABLE HEPATOCELLULAR CARCINOMA FROM A REAL WORLD STUDY

被引：0
|
作者：
Chang, Xiujuan [1 ]
Yu, Shumin [1 ,2 ]
Pang, Jianzhi [1 ]
Zhang, Wei [1 ]
Kong, Huifang [1 ]
Huang, Jiagan [1 ]
Zhang, Guojie [1 ]
Zhang, Huixin [1 ]
Gu, Yueyue [1 ,3 ]
Dong, Zheng [1 ]
Chen, Yan [1 ]
Yang, Bin [1 ]
Liu, Jingping [4 ]
Yang, Yongping [1 ]
Zeng, Zhen [1 ,2 ,3 ]
机构：
[1] Chinese Peoples Liberat Army Gen Hosp, Med Ctr 5, Beijing, Peoples R China
[2] Peking Univ, Clin Med Sch 302, Beijing, Peoples R China
[3] Anhui Med Univ, Sch Clin Med 5, Hefei, Anhui, Peoples R China
[4] Elect Power Hosp Beijing, Beijing, Peoples R China
来源：
HEPATOLOGY | 2022年 / 76卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
4402
引用
收藏
页码：S1305 / S1306
页数：2
相关论文
共 50 条
  • [21] Predicting the efficacy of lenvatinib plus anti-PD-1 antibodies in unresectable hepatocellular carcinoma (uHCC) using radiomics features of tumors extracted from baseline MRI
    Sun, H.
    Rao, S-X.
    Xu, B.
    Zhu, X-D.
    Dong, S-Y.
    Li, X-L.
    Huang, C.
    Shen, Y-H.
    Zhu, J-J.
    Li, M-L.
    Liu, J.
    Zeng, M-S.
    Zhou, J.
    Fan, J.
    ANNALS OF ONCOLOGY, 2021, 32 : S825 - S826
  • [22] Real-world efficacy and prognostic factors of lenvatinib plus PD-1 inhibitors in 378 unresectable hepatocellular carcinoma patients
    Xu Yang
    Bowen Chen
    Yanyu Wang
    Yunchao Wang
    Junyu Long
    Nan Zhang
    Jingnan Xue
    Ziyu Xun
    Linzhi Zhang
    Jiamin Cheng
    Jin Lei
    Huishan Sun
    Yiran Li
    Jianzhen Lin
    Fucun Xie
    Dongxu Wang
    Jie Pan
    Ke Hu
    Mei Guan
    Li Huo
    Jie Shi
    Lingxiang Yu
    Lin Zhou
    Jinxue Zhou
    Zhenhui Lu
    Xiaobo Yang
    Yilei Mao
    Xinting Sang
    Yinying Lu
    Haitao Zhao
    Hepatology International, 2023, 17 : 709 - 719
  • [23] Donafenib combined with anti-PD-1 antibodies plus transarterial therapy for initially unresectable hepatocellular carcinoma
    Wen, Yaohong
    Fu, Shunjun
    He, Guolin
    Cai, Lei
    Liu, Yahong
    Li, Xinmin
    Xu, Yuyan
    Wang, Chunming
    Zhong, Kaihang
    Zhang, Cheng
    Xie, Qingyu
    Pan, Mingxin
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [24] Outcomes of Salvage Surgery for Initially Unresectable Hepatocellular Carcinoma Converted by Transcatheter Arterial Chemoembolization Combined with Lenvatinib Plus Anti-PD-1 Antibodies: A Multicenter Retrospective Study
    Wu, Jia-Yi
    Zhang, Zhi-Bo
    Zhou, Jian-Yin
    Ke, Jing-Peng
    Bai, Yan-Nan
    Chen, Yu-Feng
    Wu, Jun-Yi
    Zhou, Song-Qiang
    Wang, Shuang-Jia
    Zeng, Zhen-Xin
    Li, Yi-Nan
    Qiu, Fu-Nan
    Li, Bin
    Yan, Mao-Lin
    LIVER CANCER, 2023, 12 (03) : 229 - 237
  • [25] Real-world experience of pembrolizumab plus lenvatinib in unresectable hepatocellular carcinoma in Taiwan.
    Wu, Chi-Jung
    Hung, Ya-Wen
    Lee, Pei-Chang
    Lee, ChiehJu
    Chen, Ming Huang
    Chao, Yee
    Hou, Ming-Chih
    Huang, Yi-Hsiang
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [26] Efficacy and Safety of Lenvatinib Combined With PD-1 Inhibitors Plus TACE for Unresectable Hepatocellular Carcinoma Patients in China Real-World
    Li, Xiaowei
    Fu, Zhigang
    Chen, Xiaoxia
    Cao, Kunkun
    Zhong, Jiaming
    Liu, Li
    Ding, Ning
    Zhang, Xiaoli
    Zhai, Jian
    Qu, Zengqiang
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [27] Conversion surgery for initially unresectable hepatocellular carcinoma using lenvatinib combined with TACE plus PD-1 inhibitor: A real-world observational study
    Li, Xingzhi
    Wang, Xiaobo
    Bai, Tao
    Chen, Jie
    Lu, Shaolong
    Wei, Tao
    Tang, Zhihong
    Zhao, Guilin
    Lu, Huaze
    Li, Lequn
    Wu, Feixiang
    DIGESTIVE AND LIVER DISEASE, 2024, 56 (06) : 1078 - 1086
  • [28] EFFICACY AND SAFETY OF LENVATINIB COMBINED WITH DIFFERENT ANTI-PD-1 ANTIBODY IN PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA: A REAL WORLD EVIDENCE BASED RETROSPECTIVE STUDY
    Chen, Bowen
    Zhang, Linzhi
    Cheng, Jiamin, Sr.
    Yan, Tao
    Lu, Yinying
    HEPATOLOGY, 2021, 74 : 637A - 638A
  • [29] A real-world study of the efficacy and safety of anti-PD-1 antibodies plus lenvatinib in patients with advanced gallbladder cancer
    Bangyou Zuo
    Xiaobo Yang
    Xu Yang
    Jin Bian
    Junyu Long
    Dongxu Wang
    Cong Ning
    Yanyu Wang
    Ziyu Xun
    Yunchao Wang
    Xin Lu
    Yilei Mao
    Xinting Sang
    Haitao Zhao
    Cancer Immunology, Immunotherapy, 2022, 71 : 1889 - 1896
  • [30] A real-world study of the efficacy and safety of anti-PD-1 antibodies plus lenvatinib in patients with advanced gallbladder cancer
    Zuo, Bangyou
    Yang, Xiaobo
    Yang, Xu
    Bian, Jin
    Long, Junyu
    Wang, Dongxu
    Ning, Cong
    Wang, Yanyu
    Xun, Ziyu
    Wang, Yunchao
    Lu, Xin
    Mao, Yilei
    Sang, Xinting
    Zhao, Haitao
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2022, 71 (08) : 1889 - 1896
12345